Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421442 · ClinicalTrials.gov registry record
A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 38,396
- Enrollment target
NCT05421442: Completed study, sponsored by Bristol-Myers Squibb.
NCT05421442 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 38,396 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05421442 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 38,396 participants
- Enrollment target
Study Summary
The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38,396 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2025-10-31 |
What the finished NCT05421442 record still lists
NCT05421442 is an observational study that tracks outcomes without assigning an intervention. Its 38,396 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT05421442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05421442 about?
NCT05421442 is a clinical study titled "A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database". The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
What is the current status of trial NCT05421442?
This trial is currently completed. The enrollment target is 38,396 participants. The study started on 2019-06-13. Estimated completion is 2025-10-31.
Who is sponsoring clinical trial NCT05421442?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796505 · 37,122 participants · NA
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI